Pharmacogenomics uses genetic and genomic information to predict the response of individual patients and patient populations to drugs. Pharmacogenomics will have an impact on medicine by allowing the use of newly created genomic diagnostic tools to predict which drugs will have the greatest chance of success in treating individual patients safely and effectively. Eventually, drug prescriptions may be tailored or customized to the individual patient's genetic make-up using this technology.

Pharmacogenomics also has the potential to revolutionize the planning and design of clinical trials. By identifying which patients will respond to compounds being tested, as well as by eliminating those who may be at risk of adverse reactions, pharmacogenomics can improve the success rate of clinical development and reduce development time and cost.

Axys has entered the pharmacogenomics business through the establishment of PPGx, Inc., a majority-owned subsidiary that provides comprehensive pharmacogenomics products and services to pharmaceutical and biotechnology companies worldwide. PPGx is unique among companies that offer pharmacogenomic services with customized solutions to pharmacogenomic issues in drug development. PPGx was recognized in a recent Fortune magazine article concerning the potential impact of pharmacogenetics. Our partner is xGS Tech, a leading provider of contract and consulting drug research and development services.